Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
The objective of this research is to find out what effects (good and bad), the sequence of
Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX, the standard chemotherapy
for pancreatic cancer, has on participants and their condition. Gemcitabine - Abraxane
(nab-Paclitaxel) and mFOLFIRINOX has been approved by the US Food and Drug Administration
(FDA) as first line treatment for advanced pancreatic cancer. The sequence of Gemcitabine -
Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX has not been approved by the FDA for
treatment of pancreatic cancer.